Insider Cluster (2 insiders) ·Filed Apr 6, 2026

NUVL

Nuvalent, Inc.
BEARISH
Impact 6/10
Horizondays Processed5mo ago
Insider cluster: 2 insiders, $1.4M total
Actionable Insight ▼ Bearish

Monitor for additional insider activity or commentary around upcoming earnings; while the dollar amount is not large relative to market cap, coordinated C-suite selling may signal caution at current valuation levels.

DirectionBearish
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
NUVL ▲ +19.18% at T+60d
SHORT call ✗ call lost -19.18% · α vs SPY -5.71% · entry $103.71 → $123.60
Entry anchored
Apr 2, 03:59 PM ET
via exchange tick
T+1d
-1.41%
call +1.41% · α +1.47%
$102.25
settled 6mo ago
T+5d
-0.02%
call +0.02% · α +4.15%
$103.69
settled 6mo ago
T+20d
-1.05%
call +1.05% · α +10.03%
$102.62
settled 5mo ago
T+60d
+19.18%
call -19.18% · α -5.71%
$123.60
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Nuvalent CEO and Chief Scientific Officer sold shares worth $1.4M in the past week, including a $1.17M open-market sale by the CEO. The transactions follow routine stock option exercises and are part of a broader insider cluster signaling modest selling pressure.

Key Financial Metrics

Direction
selling
Total Value
$1.4M
Insiders
2

Key Facts

  • CEO James Richard Porter sold 11,400 shares at $103.21 for $1.17M in open-market transaction.
  • Chief Scientific Officer Henry E. Pelish sold 2,193 shares at $104.27 for $229K, following derivative exercises.
  • Total insider sell volume: $1.4M over a 7-day window.
  • Sales represent approximately 0.017% of Nuvalent's $8.1B market cap — modest in scale but notable given C-suite participation.

Financial Impact

$1.4M in net insider selling over 7 days

insider ownershipinvestor sentiment

Risk Factors

  • Perception of insider pessimism despite non-cash derivative exercises being routine.
  • Potential for short-term downward pressure if selling trend continues.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-NUVL-1776112252902
18 reports for NUVL
Performance horizon
29% Hit rate 2 of 7 directional calls best @ T+60▲ +21.01%Apr 7, 2026
Filters
Rows
Reports for NUVL — sortable, filterable
TypeNow
Jul 27, 2026
9w ago
15-12G
NEUTRAL ★ 3/10
—awaiting T+5——
Jul 15, 2026
11w ago
25-NSE
NEUTRAL ★ 3/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 15, 2026
11w ago
8-K
BULLISH ★ 5/10
$123.96 $123.96· 0.00%▲ +0.98%—
Jul 8, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.80 $123.96▲ +0.13%▼ −0.73%—
Jul 6, 2026
12w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.72 $123.90▲ +0.15%▼ −0.34%—
Jun 11, 2026
16w ago
Insider Cluster
NEUTRAL ★ 2/10
$123.25 $123.43▲ +0.15%▼ −0.53%—
Jun 10, 2026
16w ago
Insider Cluster
NEUTRAL ★ 3/10
$123.45 $123.36▼ −0.07%▼ −0.51%—
Jun 9, 2026
16w ago
8-K
BULLISH ★ 8/10
$123.25 $123.35▲ +0.08%▼ −2.33%—
May 7, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$102.40 $105.22▲ +2.75%▲ +1.25%—
Apr 29, 2026
22w ago
Insider Cluster
NEUTRAL ★ 2/10
$99.10 $101.47▲ +2.39%▼ −0.72%—
Showing 10 of 18

US Market Status

Market Open — Closes in 3h 57m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published Apr 13, 2026